Member Info for Ralphiebabe

O Recruitment of further technical team members to accelerate the conversion of the pipeline and support service delivery;

This because they are unable to retain their employers, 3 have left in past 2 years ( the last 2 within the last couple of months).

Also, another 3 are only on Consultancy.

Https://www.linkedin.com/in/katherine-t-02779130b/

https://www.linkedin.com/in/katherinestully/?originalSubdomain=fr

Noticed on Mark Davies Likened page a new person working for him.

It is a Katherine T (Tully), an International Project Assistant with a background in translation.

Nathalie now at Novartis

https://www.linkedin.com/in/nathalie-dupuy-a0562521?originalSubdomain=uk

Missing from Team member is Dr Nathalie Dupuy, senior Biosimulation scientist, take it she has moved elsewhere.

Also, added another consultant.

https://www.physiomics.co.uk/about/team/

Sorry wrong Ryan

Ryan Meredith

Business Development Manager

Ryan joined AJ Bell seven years ago. Since then, he has passed multiple professional industry exams, and gained experience within a variety of operational teams across the business. He currently works alongside our North West Sales Support team, helping adviser firms to get the most from our platform, and really grow their businesses.

https://www.ajbell.co.uk/group/about-us/people/ryan-meredith

Congratulations to Ankyra Therapeutics on expanding their collaboration with Johnson & Johnson Innovative Medicine to further develop ANK-101 in solid tumours! 🎉 It's great to see this project that Physiomics plc has supported continue to progress in clinical development

https://www.linkedin.com/posts/ankyratx_anchoredimmunotherapy-anchoreddrugconjugates-activity-7283467671516397569-eI0x?utm_source=share&utm_medium=member_desktop

We’re excited to be attending the 8th Annual DDR Inhibitors Summit in Boston (28-30 Jan) next week! 🎉 This year’s discussions will be an excellent opportunity to explore the latest advancements in DDR therapies.

As DDR drug development becomes more complex, optimising dosing and selecting the right combination strategy are crucial to overcoming challenges like toxicity and resistance. That’s where our model-informed drug development (MIDD) expertise comes in. We model the synergistic effects of DDR inhibitors on tumor growth to optimise dosing and scheduling in early-phase development, helping to de-risk clinical combination development plans for our clients.

If you’re attending, reach out to Hayley Close, our Head of Business Development, to schedule a chat and learn how we support your DDR inhibitor development using MIDD.

https://lnkd.in/eUUeThyU

In Boston next week, Physiomics attending.

https://www.linkedin.com/posts/physiomics-plc_ddrinhibitors-cancertherapy-midd-activity-7288132831287906305-3DFK?utm_source=social_share_sheet&utm_medium=member_desktop_web

Peter reposted this on LinkedIn.

https://www.linkedin.com/posts/hitesh-mistry-1ba60121_its-rare-to-get-to-try-a-qsp-model-and-abm-ugcPost-7282853100015521793-_So3?utm_source=share&utm_medium=member_desktop

A Multiple-Model-Informed Drug-Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

https://ascpt.onlinelibrary.wiley.com/doi/10.1002/psp4.13297

KingHomerJ

Correct, Principal Scientist about 2 months ago, good move for him.

Another Biosimulation Scientist required, as David Hodson no longer employed by PYC by the look of it , see Team page.

Looks like no more RNS due.

Peter Sargent Sargent, CEO, shares: "This year has been an exciting chapter for Physiomics. As we look to 2025, we’re focussed on expanding our reach further, to improve outcomes at every stage of drug development and support delivery of effective therapies to the right patients. With our incredible team and the relationships that we’re building, we’re excited for what’s to come.”

We’re truly grateful to our clients, partners, investors and team for their incredible support and collaboration this year. Stay tuned to find out what lies ahead in 2025. 🎉

https://www.linkedin.com/posts/physiomics-plc_looking-ahead-to-2025-at-physiomics-plc-activity-7262472895203889152-85lX?utm_source=combined_share_message&utm_medium=member_desktop_web

Fantasy or fact, hope 2025 will show the way.

https://www.linkedin.com/posts/physiomics-plc_why-is-biostatistics-important-to-clinical-activity-7275105540622434304-gt6e?utm_source=share&utm_medium=member_desktop

Me thinks client is Bicycle, check their pipeline.

Maybe wrong as other Parma’s working on ADC.

From Peters Linkedin page.

Nice discussion around the FDA's Project Optimus and the power of Model Informed Drug Development (MIDD). We at Physiomics brings decades of experience supporting biopharma leverage MIDD techniques and tools in order to move from Maximum Tolerated Dose to Optimal Biological Dose - accelerating drug development and improving patient outcomes

https://www.linkedin.com/feed/update/urn:li:activity:7269717708051517440/

Data analysis and model evaluation of chemotherapy induced neutropenia

Results from the PARTNER.

https://www.physiomics.co.uk/wp-content/uploads/2024/11/Data-analysis-and-model-evaluation-of-chemotherapy-induced-neutropenia-Results-from-the-PARTNER-trial_EORTC-2024.pdf

Team site updated, includes Mark Davies.

https://www.physiomics.co.uk/about/team/

Trade has been corrected.

Recent Share Trades for Physiomics (PYC)

Date Time Trade Prc Volume Buy/Sell Bid Ask Value

08-Nov-24 16:35:29 0.70 6,023,170 Unknown* 0.65 0.75 42.16k O

08-Nov-24 16:35:29 70.00 -6,023,170 Unknown* 0.65 0.75 -4m O

08-Nov-24 16:35:29 70.00 6,023,170 Unknown* 0.65 0.75 4m O

08-Nov-24 15:20:29 0.669 120,000 Sell* 0.65 0.75 802.80